Drug Profile
Tigatuzumab
Alternative Names: CS-1008; TRA-8Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company; University of Alabama at Birmingham
- Developer Daiichi Sankyo Company
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Colorectal cancer; Liver cancer; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Triple negative breast cancer
Most Recent Events
- 01 Jun 2017 University of Alabama at Birmingham and Daiichi Sankyo completes a phase II trial for Breast cancer (Combination therapy; Metastatic disease) in the US (NCT01307891)
- 31 Oct 2013 Discontinued - Phase-I for Lymphoma in USA (IV)
- 31 Oct 2013 Discontinued - Phase-II for liver cancer in Japan (IV)